Related Experiment Video

Updated: Mar 16, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and

Thomas Denèfle1,2,3, Héloise Boullet1,2, Linda Herbi4,5,6

  • 1Sorbonne Universités, UPMC Université Paris 06, Ecole Normale Supérieure, CNRS, Laboratoire des Biomolécules, 75005 Paris, France.

Journal of Medicinal Chemistry
|August 17, 2016
PubMed

Insights

A novel peptide derived from Thrombospondin-1 (TSP-1) selectively induces cancer cell death. This TSP-1 mimetic peptide shows promise for developing new targeted anticancer therapies by targeting the CD47 receptor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Thrombospondin-1 (TSP-1) is a crucial glycoprotein in the tumor microenvironment.
  • TSP-1 binding to the CD47 receptor initiates programmed cell death (PCD).
  • The 4N1K decapeptide is derived from the TSP-1/CD47 binding site.

Purpose of the Study:

  • To investigate the therapeutic potential of the 4N1K decapeptide.
  • To develop a serum-stable TSP-1 mimetic peptide targeting CD47.
  • To evaluate the selective induction of cancer cell apoptosis.

Main Methods:

  • Structure-activity relationship (SAR) studies of TSP-1 derived peptides.
  • In vitro testing of peptide-induced apoptosis in various cancer cell lines.
  • Assessment of peptide stability and selectivity against normal cells.

Main Results:

  • The 4N1K decapeptide selectively induces apoptosis in multiple cancer cell lines (lung, breast, colorectal).
  • Normal cells remain unaffected by the peptide treatment.
  • A stable TSP-1 mimetic peptide agonist was successfully designed.

Conclusions:

  • The developed TSP-1 mimetic peptide is a potent CD47 agonist.
  • This peptide effectively triggers selective cancer cell death.
  • These findings offer new avenues for developing innovative anticancer treatments targeting CD47.

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

18.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K